Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain

Journal of Virology

Volumn 79, Issue 21, 2005, Pages 13338-13349

  Lian, Ying ^a   Srivastava, Indresh ^a   Gómez Román, V Rául ^a   Zur Megede, Jan ^a   Sun, Yide ^a   Kan, Elaine ^a   Hilt, Susan ^a   Engelbrecht, Susan ^b   Himathongkham, Sunee ^c,f   Luciw, Paul A ^c   Otten, Gillis ^a   Ulmer, Jeffrey B ^a   Donnelly, John J ^a   Rabussay, Dietmar ^e   Montefiori, David ^d   Van Rensburg, Estrelita Janse ^b,g   Barnett, Susan W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Inovio Biomedical Corporation   (United States)

^f Food and Drug Laboratory Branch   (United States)

^g UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DERIVATIZATION; EVALUATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE C; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; SOUTH AFRICA; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS STRAIN;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; DRUG EVALUATION, PRECLINICAL; GENE DELETION; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; RABBITS; SEQUENCE ALIGNMENT; SOUTH AFRICA; VACCINATION; VACCINES, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; ORYCTOLAGUS CUNICULUS;

EID: 27144524041     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.21.13338-13349.2005     Document Type: Article

References (32)

1. Barnett, S. W., S. Lu, I. Srivastava, S. Cherpelis, A. Gettie, J. Blanchard, S. Wang, I. Mboudjeka, L. Leung, Y. Lian, A. Fong, C. Buckner, A. Ly, S. Hilt, J. Ulmer, C. T. Wild, J. R. Mascola, and L. Stamatatos. 2001. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75:5526-5540.
2. Barouch, D. H., J. Kunstman, M. J. Kuroda, J. E. Schmitz, S. Santra, F. W. Peyerl, G. R. Krivulka, K. Beaudry, M. A. Lifton, D. A. Gorgone, D. C. Montefiori, M. G. Lewis, S. M. Wolinsky, and N. L. Letvin. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335-339.
3. Cherpelis, S., X. Jin, A. Gettie, D. D. Ho, S. W. Barnett, I. Srivastava, and L. Stamatatos. 2001. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques. Immunol. Lett. 79:47-55.
4. + T-cell-depleted rhesus macaques. J. Virol. 75:1547-1550.
5. Engelbrecht, S., T. de Villiers, C. C. Sampson, J. zur Megede, S. W. Barnett, and E. J. van Rensburg. 2001. Genetic analysis of the complete gag and env genes of HIV type 1 subtype C primary isolates from South Africa. AIDS Res. Hum. Retrovir. 17:1533-1547.
6. Esparza, J., and N. Bhamarapravati. 2000. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 355:2061-2066.
7. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B. H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360.
8. Graham, B. S. 2000. Clinical trials of HIV vaccines: HIV database. [Online.] http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/GRAHAM2000/Graham .html.
9. Haas, J., E. Park, and B. Seed. 1996. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6:315-324.
10. Johnson, W. E., J. Morgan, J. Reitter, B. A. Puffer, S. Czajak, R. W. Doms, and R. C. Desrosiers. 2002. A replication-competent, neutralization- sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J. Virol. 76:2075-2086.
11. Johnston, M. I., and J. Flores. 2001. Progress in HIV vaccine development. Curr. Opin. Pharmacol. 1:504-510.
12. Korber, B., M. Muldoon, J. Theiler, F. Gao, R. Gupta, A. Lapedes, B. H. Hahn, S. Wolinsky, and T. Bhattacharya. 2000. Timing the ancestor of the HIV-1 pandemic strains. Science 288:1789-1796.
13. Lu, S., R. Wyatt, J. F. Richmond, F. Mustafa, S. Wang, J. Weng, D. C. Montefiori, J. Sodroski, and H. L. Robinson. 1998. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with or without deletions in the V1/2 and V3 regions. AIDS Res. Hum. Retrovir. 14:151-155.
14. Mascola, J. R., M. G. Lewis, G. Stiegler, D. Harris, T. C. VanCott, D. Hayes, M. K. Louder, C. R. Brown, C. V. Sapan, S. S. Frankel, Y. Lu, M. L. Robb, H. Katinger, and D. L. Birx. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
15. Montefiori, D. C. 2004. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in a luciferase reporter gene assay. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, and R. Coico (ed.), Current protocols in immunology, in press. John Wiley & Sons, Inc., New York, N.Y.
16. Moore, J. P., P. W. Parren, and D. R. Burton. 2001. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J. Virol. 75:5721-5729.
17. Osmanov, S., C. Pattou, N. Walker, B. Schwardlander, and J. Esparza. 2002. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquir. Immune Defic. Syndr. 29:184-190.
18. Otten, G., M. Schaefer, B. Doe, H. Liu, I. Srivastava, J. zur Megede, D. O'Hagan, J. Donnelly, G. Widera, D. Rabussay, M. G. Lewis, S. Barnett, and J. B. Ulmer. 2004. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22:2489-2493.
19. Robert-Guroff, M., H. Kaur, L. J. Patterson, M. Leno, A. J. Conley, P. M. McKenna, P. D. Markham, E. Richardson, K. Aldrich, K. Arora, L. Murty, L. Carter, S. Zolla-Pazner, and F. Sinangil. 1998. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J. Virol. 72:10275-10280.
20. Shankarappa, R., R. Chatterjee, G. H. Learn, D. Neogi, M. Ding, P. Roy, A. Ghosh, L. Kingsley, L. Harrison, J. I. Mullins, and P. Gupta. 2001. Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences. J. Virol. 75:10479-10487.
21. Srivastava, I. K., L. Stamatatos, E. Kan, M. Vajdy, Y. Lian, S. Hilt, L. Martin, C. Vita, P. Zhu, K. H. Roux, L. Vojtech, D. C. Montefiori, J. Donnelly, J. B. Ulmer, and S. W. Barnett. 2003. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol. 77:11244-11259.
22. Stamatatos, L., and C. Cheng-Mayer. 1998. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 72:7840-7845.
23. Sullivan, N., Y. Sun, Q. Sattentau, M. Thali, D. Wu, G. Denisova, J. Gershoni, J. Robinson, J. Moore, and J. Sodroski. 1998. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72:4694-4703.
24. Treurnicht, F., T. Smith, S. Engelbrecht, M. Claassen, B. Robson, M. Zeier, and E. van Rensburg. 2002. Genotypic and phenotypic analysis of the env gene from South African HIV-1 subtype B and C isolates. J. Med. Virol. 68:141-146.
25. UNAIDS/World Health Organization. 2004. Report on the global AIDS epidemic. World Health Organization, Geneva, Switzerland. http://www. unaids.org/bangkok 2004/report.html. [Online.]
26. van Harmelen, J. H., E. Shephard, R. Thomas, T. Hanke, A. L. Williamson, and C. Williamson. 2003. Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine 21:4380-4389.
27. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Komarova, M. A. Nowak, B. H. Hahn, P. D. Kwong, and G. M. Shaw. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
28. Widera, G., M. Austin, D. Rabussay, C. Goldbeck, S. W. Barnett, M. Chen, L. Leung, G. R. Otten, K. Thudium, M. J. Selby, and J. B. Ulmer. 2000. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164:4635-4640.
29. Williamson, C., L. Morris, M. F. Maughan, L. H. Ping, S. A. Dryga, R. Thomas, E. A. Reap, T. Cilliers, J. van Harmelen, A. Pascual, G. Ramjee, G. Gray, R. Johnston, S. A. Karim, and R. Swanstrom. 2003. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res. Hum. Retrovir. 19:133-144.
30. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
31. Zolla-Pazner, S., M. Lubeck, S. Xu, S. Burda, R. J. Natuk, F. Sinangil, K. Steimer, R. C. Gallo, J. W. Eichberg, T. Matthews, and M. Robert-Guroff. 1998. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J. Virol. 72:1052-1059.
32. zur Megede, J., S. Engelbrecht, T. de Oliveira, S. Cassol, T. J. Scriba, E. J. van Rensburg, and S. W. Barnett. 2002. Novel evolutionary analyses of full-length HIV type 1 subtype C molecular clones from Cape Town, South Africa. AIDS Res. Hum. Retrovir. 18:1327-1332.